Innovations 2024 en néphrologie

Demoulin, Nathalie;El Kesri, Mohamed Amine;Van Regemorter, Elliott;Fernandes, Guillaume;Kanaan, Nada;et.al.
(2025) Louvain médical — Vol. 144, n° 2, p. 85-89 (2025)

Files

2025_LM_Innovations_Néphrologie.pdf
  • Open Access
  • Adobe PDF
  • 1.5 MB
Download

Details

Authors
Show more
Abstract
(en) [Innovations 2024 in nephrology] The year 2024 saw significant advances in the therapeutic management of patients with IgA nephropathy. Strict control of proteinuria is essential to slow down the progression to kidney failure. The first immunomodulatory agent to target the pathogenesis of IgA nephropathy is now available in Belgium, and promising new targeted therapies are being investigated. In kidney transplantation, the prophylaxis and treatment of CMV disease have benefited from the advent of new drugs. Since March 2024, maribavir has been reimbursed in Belgium for the treatment of refractory or resistant CMV disease, or in cases of intolerance to treatment due to myelotoxicity or nephrotoxicity.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Demoulin, N., El Kesri, M. A., Van Regemorter, E., Fernandes, G., Dufour, I., Gillion, V., Labriola, L., Jadoul, M., Goffin, E., Devresse, A., & Kanaan, N. (2025). Innovations 2024 en néphrologie. Louvain médical, 144(2), 85-89. https://hdl.handle.net/2078.5/267488 (Original work published 2025)